Radiation dose-response model for locally advanced rectal cancer after preoperative chemoradiation therapy

Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):74-80. doi: 10.1016/j.ijrobp.2012.05.017. Epub 2012 Jul 3.


Purpose: Preoperative chemoradiation therapy (CRT) is part of the standard treatment of locally advanced rectal cancers. Tumor regression at the time of operation is desirable, but not much is known about the relationship between radiation dose and tumor regression. In the present study we estimated radiation dose-response curves for various grades of tumor regression after preoperative CRT.

Methods and materials: A total of 222 patients, treated with consistent chemotherapy and radiation therapy techniques, were considered for the analysis. Radiation therapy consisted of a combination of external-beam radiation therapy and brachytherapy. Response at the time of operation was evaluated from the histopathologic specimen and graded on a 5-point scale (TRG1-5). The probability of achieving complete, major, and partial response was analyzed by ordinal logistic regression, and the effect of including clinical parameters in the model was examined. The radiation dose-response relationship for a specific grade of histopathologic tumor regression was parameterized in terms of the dose required for 50% response, D50,i, and the normalized dose-response gradient, γ50,i.

Results: A highly significant dose-response relationship was found (P=.002). For complete response (TRG1), the dose-response parameters were D50,TRG1=92.0 Gy (95% confidence interval [CI] 79.3-144.9 Gy), γ50,TRG1=0.982 (CI 0.533-1.429), and for major response (TRG1-2) D50,TRG1&2=72.1 Gy (CI 65.3-94.0 Gy), γ50,TRG1&2=0.770 (CI 0.338-1.201). Tumor size and N category both had a significant effect on the dose-response relationships.

Conclusions: This study demonstrated a significant dose-response relationship for tumor regression after preoperative CRT for locally advanced rectal cancer for tumor dose levels in the range of 50.4-70 Gy, which is higher than the dose range usually considered.

Publication types

  • Clinical Trial, Phase II
  • Clinical Trial, Phase III
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / pathology
  • Adenocarcinoma / therapy*
  • Adult
  • Aged
  • Brachytherapy / methods
  • Chemoradiotherapy / methods*
  • Dose-Response Relationship, Radiation
  • Female
  • Humans
  • Logistic Models
  • Male
  • Middle Aged
  • Models, Biological
  • Neoplasm Staging
  • Patient Selection
  • Preoperative Care / methods
  • Radiotherapy Dosage
  • Rectal Neoplasms / pathology
  • Rectal Neoplasms / therapy*
  • Remission Induction / methods
  • Tegafur / administration & dosage
  • Tumor Burden
  • Uracil / administration & dosage
  • Watchful Waiting*


  • Tegafur
  • Uracil